⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862393 | 0.84 | CA12 (0.38) | — | |
| SCHEMBL9543583 | 0.82 | CA12 (0.40) | — | |
| SCHEMBL3346318 | 0.77 | — | — | |
| SCHEMBL6228460 | 0.74 | — | — | |
| SCHEMBL4413907 | 0.74 | — | — | |
| SCHEMBL25450601 | 0.72 | — | — | |
| SCHEMBL12744867 | 0.72 | — | — | |
| SCHEMBL3345449 | 0.72 | — | — | |
| SCHEMBL1742138 | 0.69 | ACHE (0.31) | — | |
| SCHEMBL8509049 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| EP-0284375-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-09-28 | — | — | EP | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| CN-100566712-C | Polyamine compounds for the treatment of chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY CO LTD (CN) | 2009-12-09 | — | — | CN | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| CN-1798551-A | Polyamine compounds for the treatment of chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY CO LTD (CN) | 2006-07-05 | — | — | CN | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
| US-4859779-A | ENZYME INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4837353-A | 2-/N-PHENYLALKYL-N-FORMYL/AMINO-3-HYDROXY-2-PROPENOIC ACID DERIVATIVES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0284375-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-09-28 | — | — | EP | disclosed |
| US-4762850-A | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1988-08-09 | — | — | US | disclosed |